Komori
Revision of earnings forecasts4521KAKEN PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding the Revision of Consolidated Earnings Forecasts for the Fiscal Year Ending March 2026 Following the Achievement of a Milestone Under the License Agreement with Johnson & Johnson and Receipt of Milestone Income

The consolidated earnings forecast for the fiscal year ending March 2026 has been revised downward. The recognition of milestone income from J&J has been deferred to the fiscal year ending March 2027, reducing the revenue and profit forecasts, and operating and ordinary losses are now forecast.

Worth reading
64In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Deterioration
Direction inferred from the company’s description.
Scale
-9400
¥ million
Wording
Conditional
How definitive the wording is.

Revised forecast

Fiscal year ending March 2026 · Full yearPrevious forecast published 26 September 2025
Net Sales86,300→76,900million
-10.9%
Operating profit2,100→-900million
-142.9%
Ordinary income2,800→-200million
-107.1%
Profit attributable to owners of the parent2,300→2,100million
-8.7%
Net income per share—→—yen
—

The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.

Reason for the revision

The milestone was achieved in April 2026, resulting in the milestone income being recognized in the fiscal year ending March 2027. The revision also reflects the effects of measures including more efficient R&D investment and the sale of cross-shareholdings.

Previous-period resultsFiscal Period Covered Fiscal year ending March 2025 / Net Sales ¥94,035 million / Operating profit ¥21,034 million / Ordinary income ¥21,279 million / Profit attributable to owners of the parent ¥13,945 million / Net income per share ¥365.42
Dividend forecast revisionNo revision
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net Sales¥86,300 million → ¥76,900 million(-10.9%)
Operating profit¥2,100 million → ¥-900 million
Ordinary income¥2,800 million → ¥-200 million
Profit attributable to owners of the parent¥2,300 million → ¥2,100 million(-8.7%)
Net income per share¥60.74 → ¥55.39
Fiscal Period CoveredFiscal year ending March 2026
Period CoveredFull year
Publication date of previous forecast26 September 2025
Previous-period resultsFiscal Period Covered Fiscal year ending March 2025 / Net Sales ¥94,035 million / Operating profit ¥21,034 million / Ordinary income ¥21,279 million / Profit attributable to owners of the parent ¥13,945 million / Net income per share ¥365.42
Reason for the revisionThe milestone was achieved in April 2026, resulting in the milestone income being recognized in the fiscal year ending March 2027. The revision also reflects the effects of measures including more efficient R&D investment and the sale of cross-shareholdings.
Dividend forecast revisionNo revision
Consolidated / non-consolidatedConsolidated
Items this document does not state (1)
Details and amount of extraordinary loss

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This revision reflects the milestone being achieved in April 2026, resulting in the income being recognized in the fiscal year ending March 2027, as well as the effects of measures including more efficient and reduced R&D investment and the sale of cross-shareholdings in line with the policy of focusing on medium- to long-term growth.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Revision of Consolidated Earnings Forecasts for the Fiscal Year Ending March 2026 Following the Achievement of a Milestone Under the License Agreement with Johnson & Johnson and Receipt of Milestone Income | KAKEN PHARMACEUTICAL CO.,LTD. (4521) timely disclosure | Komori